<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jen-Fu</forename><surname>Yang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheng-Hsiang</forename><surname>Lo</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Meei-Shyuan</forename><surname>Lee</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun-Shu</forename><surname>Lin</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yang-Hong</forename><surname>Dai</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Po-Chien</forename><surname>Shen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hsing-Lung</forename><surname>Chao</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wen-Yen</forename><surname>Huang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Radiation Oncology</orgName>
								<orgName type="department" key="dep2">Tri-Service General Hospital</orgName>
								<orgName type="institution">National Defense Medical Center</orgName>
								<address>
									<addrLine>No. 325, Sec. 2, Cheng-Kong Rd. Nei-Hu</addrLine>
									<postCode>11490</postCode>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1186/s13014-019-1382-1</idno>
					<note type="submission">Received: 26 February 2019 Accepted: 23 September 2019</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Hepatocellular carcinoma</term>
					<term>Portal vein invasion</term>
					<term>Portal vein thrombosis</term>
					<term>Stereotactic ablative radiotherapy</term>
					<term>Stereotactic body radiotherapy</term>
					<term>Conventionally fractionated radiotherapy</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: This study aimed to compare the clinical outcomes of stereotactic ablative radiotherapy (SABR) and conventionally fractionated radiotherapy (CFRT) in hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). Methods: HCC patients with PVI treated with radiotherapy from 2007 to 2016 were analysed. CFRT was administered at a median dose of 51.5 Gy (interquartile range, 45-54 Gy) with 1.8-3 Gy per fraction. SABR was administered at a median dose of 45 Gy (interquartile range, 40-48 Gy) with 6-12.5 Gy per fraction. Treatment efficacy, toxicity, and associated predictors were assessed. Results: Among the 104 evaluable patients (45 in the SABR group and 59 in the CFRT group), the overall response rate (ORR, complete and partial response) was significantly higher in the SABR group than the CFRT group (62.2% vs. 33.8%, p = 0.003). The 1-year overall survival (OS) rate (34.9% vs. 15.3%, p = 0.012) and in-field progression-free survival (IFPS) rate (69.6% vs. 32.2%, p = 0.007) were also significantly higher in the SABR vs. CFRT group. All 3 rates remained higher in the SABR group after propensity score matching. Multivariable analysis identified SABR and a biologically effective dose ≥65 Gy as favourable predicators of OS. There was no difference between treatment groups in the incidence of radiation-induced liver disease or increase of Child-Pugh score ≥ 2 within 3 months of radiotherapy. Conclusions: SABR was superior to CFRT in terms of ORR, OS, and IFPS. We suggest that SABR should be the preferred technique for HCC patients with PVI.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p>Portal vein invasion (PVI) frequently develops in patients with advanced hepatocellular carcinoma (HCC), and has an estimated incidence rate of 34 to 80% <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. Without treatment, PVI prognosticates extremely poor prognosis with a median survival of only 2.7 months <ref type="bibr" target="#b2">[3]</ref>. Sorafenib is currently regarded as the standard systemic therapy for HCC with PVI, but the survival gain is only 2-3 months <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b6">[6]</ref><ref type="bibr" target="#b7">[7]</ref>.</p><p>For various locoregional modalities including surgical resection, transarterial chemoembolization (TACE), transarterial radioembolization, hepatic artery infusion chemotherapy attempted in patients with PVI, only carefully selected patients are amendable. Radiotherapy (RT) presents the only noninvasive alternative which is not dependent on vasculature to access the tumor, and is therefore not associated with a risk of hepatic ischemia. Over the past few decades, the development of the threedimensional conformal technique has allowed for partial liver irradiation. Studies of conventionally fractionated radiotherapy (CFRT) in PVI have shown improved outcomes, with 1-year overall survival (OS) of 16.7-40.2% and overall response rates (ORR) of 23.5-45% <ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref><ref type="bibr" target="#b10">[10]</ref><ref type="bibr" target="#b11">[11]</ref><ref type="bibr" target="#b12">[12]</ref>.</p><p>Stereotactic ablative radiotherapy (SABR) is an emerging technique, and can achieve tumorcidal doses in limited fractions, with significant normal tissue sparing. Several studies have reported favorable results with SABR for treating different cancers <ref type="bibr" target="#b13">[13,</ref><ref type="bibr" target="#b14">14]</ref>. We hypothesized that SABR would provide more benefit than would CFRT in HCC patients with PVI.</p><p>The aim of this study was to present a single-institutional experience with a relatively large number of patients, and to compare the difference in clinical outcomes between the two RT techniques.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p>After obtaining waiver of consent for this retrospective research from the institutional review board of Tri-Service General Hospital (approval number: 1-107-05-016), we identified HCC patients with PVI undergoing RT from January 2007 to December 2016. Patients with Vp3/Vp4 invasion (invading the firstorder branches and/or main trunk of the portal vein), an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and a Child-Pugh (CP) class of A or B were eligible. Any prior interventions were allowed, except for previous RT. Those patients were considered unsuitable for standard locoregional treatment via multidisciplinary committee discussion. Given increasing evidence of the benefits of SABR for HCC patients in the past decades, our hospital practice naturally shifted from use of CFRT to use of SABR. Because SABR was not reimbursed until 2015 in Taiwan, the choice of RT technique was determined partly by the patients' financial resources.</p><p>Diagnosis of HCC was made either by biopsy or by radiologic investigation based on characteristic imaging findings <ref type="bibr" target="#b15">[15]</ref>. PVI was confirmed as a low-attenuation intraluminal mass that expanded the portal vein on contrast-enhanced helical computed tomography (CT) scans or on magnetic resonance imaging (MRI) scans. Pretreatment evaluation consisted of medical history, physical examination, complete blood counts, serum biochemistries, alpha-fetoprotein (AFP) level, chest film, and MRI and/or CT of the abdomen. Bone scan, positron emission tomography, or liver angiography was performed if clinically indicated.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CFRT technique</head><p>For better delineation of the upper gastrointestinal tract, most patients were asked to take oral contrast medium before simulation. A non-contrast CT simulation with a 3 mm slice thickness was performed. During the scanning procedure, all patients were supine, and were immobilized with a vacuum cushion, with arms raised overhead. Motion management with four-dimensional CT was conducted in some patients. Breath-holding was not mandatory. Either three dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy was designated, depending on the physicians' discretion, using the Nucletron Plato RTS v2.6.3 planning system, which was replaced by Philips Pinnacle v9.0 planning system in 2009. Instead of defining a gross target volume, the clinical target volume (CTV) was contoured directly. Contrast images registration was used to assist CTV delineation. The CTV was defined as a margin of 3-5 mm around the detectable PVI. Partial hepatic tumor was included in the CTV if the primary hepatic tumor was near to the detectable PVI or if the portal vein was invaded by the tumor directly. An example of target delineation is shown in <ref type="figure" target="#fig_0">Fig. 1</ref>. The planning target volume (PTV) was generated by expanding the CTV by 8 mm radially and by 10-15 mm craniocaudaully. Prescribed dose to the PTV was 45-54 Gy (1.8-3 Gy per fraction, five fractions per week), administered with a 15 MV photon beam. Most PTV was encompassed in the 90% isodose curve. The irradiation field contained 3-6 gantry angles. RT was delivered using an Elekta Precise or a Siemens Primus linear accelerator.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SABR technique</head><p>SABR was administered using the CyberKnife radiosurgery system (Accuray, Sunnyvale, CA), delivering 6 MV photons. At least one week before CT simulation, 4-6 fiducial markers were placed within or around the tumor under sonographic or CT guidance. An individually shaped vacuum pillow allowed patient immobilization in the supine position, with a vest for synchrony tracking and with abdominal compression devices to reduce respiratory motion. A contrast CT scan with a 1 mm slice thickness was obtained for treatment planning with or without MRI scan registration. The definition of CTV in SABR was the same as in the CFRT technique. The PTV was defined as the volume with a margin of 0-3 mm added to CTV for patients with fiducial implantation. If fiducial implantation failed or was unsuitable, the PTV margin was expanded to 8-20 mm craniocaudally, based on the liver motion. Margin modification was permitted for respecting normal tissue tolerance. Prior to August 2009, the MultiPlan CyberKnife treatment planning system version 1.7.0 was employed for treatment planning, and was updated to version 2.1.0 thereafter. The median total dose was 45 Gy, at 6-12.5 Gy per fraction, with 4 to 5 fractions  administered on consecutive working days. The detailed dose-limiting organs and their constraints are described in our previous publication <ref type="bibr" target="#b16">[16]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Evaluation and follow up</head><p>All patients were seen at least once per week during RT, 1-2 months for the first six months after RT, and every three months thereafter. Image evaluation with CT or MRI was obtained every 1-3 months. Modified Response Evaluation Criteria in Solid Tumors was used for evaluation of the PVI response <ref type="bibr" target="#b17">[17]</ref>.</p><p>Hepatic toxicity assessment consisted of Radiationinduced liver disease (RILD) and increase of CP score ≥ 2. Only patients with either adequate follow-up of three months or death and/or occurrence of toxicity within 3 months were included in the analysis. Physical examinations and blood tests conducted at every visit, were used for toxicity assessment. RILD was defined as either classic or non-classic, without intrahepatic tumor progression noted within three months after RT. Classic RILD manifested as the presence of nonmalignant ascites and the elevation of anicteric alkaline phosphatase level to at least twice the upper normal values. Non-classic RILD manifested as the elevation of transaminase levels to at least five times the upper limit of the normal or pre-treatment values.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p>Doses were converted to biologically effective doses (BED) with an α/β ratio of 10 for analysis. Betweengroup comparisons were conducted by chi-square tests or by Student's t-tests as appropriate. OS was measured from the first day of RT until the date of death from any cause or last follow-up. In-field progression-free survival (IFPS) was measured from the first day of RT until the date of tumor recurrence or progression in irradiated field or last follow-up and patients who have received local intervention (ex, surgery or reirradiation) were censored at the date of procedure. Kaplan Meier curves were constructed for OS and IFPS, and the difference was compared using the log-rank test. The Cox Proportional Hazards model was applied to identify potential  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient characteristics</head><p>Initially, 186 patients were identified by chart review. Forty-six patients were excluded owing to ineligibility, missing data or loss of follow-up after RT <ref type="figure" target="#fig_1">(Fig. 2)</ref>. Finally, 140 patients were entered for data analysis. SABR was administered to 54 patients (median dose, 45 Gy; inter-quartile range [IQR], 40-48 Gy; 6-12.5 Gy per fraction), and CFRT was administered to 86 patients (median dose, 51.5; IQR, 45-54 Gy; 1.8-3 Gy per fraction). Detailed patient characteristics are listed in <ref type="table" target="#tab_1">Table 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PVI response</head><p>Follow-up images were available for 45 SABR patients and for 59 CFRT patients (83.3% vs. 68.6%, p = 0.052). Among evaluable patients, five complete response, 23 partial response, 15 stable disease, and two progressive disease cases were observed in the SABR group, and five complete response, 15 partial response, 27 stable disease, and 12 progressive disease cases were observed in the CFRT group. The ORR (complete and partial response) was significantly higher in the SABR group than it was in the CFRT group (62.2% vs. 33.9%, p = 0.004). Of all patients, 18 in the SABR group and 13 in the CFRT group were able to achieve either complete or partial recanalization of the invaded vein (33.3% vs. 15.1%, p = 0.012); subsequent TACE was conducted in 9 patients of the SABR group and in 11 patients of the CFRT group (16.7% vs. 12.8%, p = 0.524).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival</head><p>The median follow-up period was 6.2 months for all patients and 15.4 months for those alive. At the time of the analysis, nine patients in the SABR group and four patients in the CFRT group were alive. Before propensity score matching, the median survival was 10.9 months in the SABR group and 4.7 months in the CFRT group. The 1-and 2-year OS rates were 34.9% and 15.3% in the SABR group, and 15.7% and 8.0% in the CFRT group, respectively (p = 0.005, <ref type="figure">Fig. 3a</ref>). The 1-and 2-year IFPSs were also significantly higher in the SABR group compared to those in the CFRT group (69.6% vs. 39.8 and 32.2% vs. 24.2%, respectively; p = 0.007; <ref type="figure">Fig. 3b</ref>).</p><p>After propensity score-matching, 49 patients in each group were matched. ( <ref type="table" target="#tab_2">Table 2</ref>). The median survival was 10.7 months in the SABR group and 5.1 months in the CFRT group. The 1-and 2-year OS and IFPSs of the SABR group were significantly higher than those of the CFRT group (OS: 33.1% vs. 16.5% and 17.3% vs. 5.2%, p = 0.01, respectively; <ref type="figure" target="#fig_2">Fig. 4a</ref>; IFPS: 70.8% vs. 39.3% and 22.2% vs. 22.2%, p = 0.002, respectively; <ref type="figure" target="#fig_2">Fig. 4b</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Predictors for survival</head><p>Univariable analysis revealed that the presence of SABR, ECOG 0-1, CP class A, single tumor, tumor size ≤8 cm, Vp3, AFP ≤200 ng/ml, prior treatment, and BED ≥65 Gy were predictors of superior OS. No survival difference was noted between patients treated before December 31, 2011 versus after December 31, 2011. Given the presence of the high correlation between BED and the RT <ref type="figure">Fig. 3</ref> Overall survival (a) and in-field progression-free survival (b) in the entire cohort using Kaplan Meier method technique (p &lt; 0.001), these variables were analyzed by two different Cox models to avoid collinearity. The presence of SABR and BED ≥65 Gy correlated significantly with superior OS in separate multivariable analysis models <ref type="table" target="#tab_4">(Table 3</ref>). Furthermore, we identified that the SABR group with BED ≥65Gy showed a higher survival rate than the CFRT group with BED &lt; 65Gy (p = 0.005) ( <ref type="figure" target="#fig_3">Fig. 5)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicity</head><p>Acute toxicities observed in the groups are shown in <ref type="table" target="#tab_5">Table 4</ref>. Fatigue was the most common adverse event in both groups. Grade 3 abdominal pain (n = 1) in the SABR group, and grade 3 diarrhea (n = 2) in the CFRT group were recorded. One patient in CFRT group presented with a treatment-related grade 5 duodenal ulcer.</p><p>Seven patients (13%) in the SABR group and 11 patients (12.8%) in the CFRT group experienced nonclassic RILD, while two patients (3.7%) in the SABR group and six patients (7%) in the CFRT group experienced classic RILD. The incidences of RILD were not different between groups, even after pooling RILD types <ref type="bibr">(16.7% vs. 19</ref>.8%, p = 0.646). There were no RILD-related deaths. After excluding 23 patients with missing follow-up CP scores, 10 patients (22.2%) in the SABR group and 19 patients (26.4%) in the CFRT group experienced an increase of CP score ≥ 2, which was not statistically different between groups (p = 0.612).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Although CFRT has benefits in PVI, the long-term outcome is still poor. Thus, more effective and promising treatments like SABR need to be explored. Unlike previous CFRT series, most SABR series have included few or no patients with PVI; the efficacy of SABR in PVI is thus not clear. A few SABR series including only PVI patients have reported a 1-year OS of 43.2-50.3% and an ORR of 44.4-86.3% <ref type="bibr" target="#b18">[18]</ref><ref type="bibr" target="#b19">[19]</ref><ref type="bibr" target="#b20">[20]</ref>. Bujold et al. <ref type="bibr" target="#b21">[21]</ref> have conducted the largest prospective trial of SABR for  advanced HCC with 112 patients, of whom 55% presented with portal vein thrombosis (PVT). The overall 1-year OS was 44%, but the outcomes of the PVT subgroup were not reported. Until now, direct head-to-head comparisons between different RT techniques in HCC with PVI have remained rare and controversial. In a cohort of patients with either PVT or inferior vena cava tumor thrombosis, Matsuo et al. <ref type="bibr" target="#b22">[22]</ref> treated 43 patients with SABR (27 with Cyber-Knife and 16 with TrueBeam) and 54 patients with CFRT. The 1-year OS rate with SABR (using Cyber-Knife) was significantly higher than that with CFRT (56.7% vs. 29.3%, p = 0.02); similar trends were observed with local control and tumor response. In the metaanalysis performed by Rim et al. <ref type="bibr" target="#b23">[23]</ref>, SABR did not improve survival rates relative to CFRT in PVT patients.</p><p>With only single-arm studies enrolled in their analysis, pooled estimates may not reveal the true head-to-head comparison as the heterogeneous designs and populations among studies. In the present study, the survival rates appear to be inferior to the published pooled results <ref type="bibr" target="#b23">[23]</ref>, in which the tumor size is much smaller than our cohort, with a median tumor size of 1.5-2.5 cm in the published pooled SABR cohort when compared with the median tumor size of 7.8 cm in our SABR cohort. However, when we analyzed only the outcome of tumors with ≤8 cm (median size: 5.1 cm) in our SABR series, the 1-year OS was 50% (data not shown), which is comparable to the 1-year OS of 48.5% in the pooled results. Tumor characteristics might partly explain the survival difference. Since some other factors affect survival as well, propensity score matching in the present study showed  that SABR was superior to CFRT in terms of ORR, OS, and IFPS. Some studies reported a higher prescribed dose or BED was correlated with better LC or survival <ref type="bibr" target="#b24">[24]</ref><ref type="bibr" target="#b25">[25]</ref><ref type="bibr" target="#b26">[26]</ref>.</p><p>According to our multivariable model, a BED ≥65 Gy was found to be a predictor of survival prolongation. We further used a ROC curve to define optimal cut-off points for separate groups. Interestingly, higher BED was associated with better survival and ORR in the CFRT group, while no optimal cut-off point was found in the SABR group. In a CFRT series, Kim et al. <ref type="bibr" target="#b27">[27]</ref> have reported that PVT patients receiving BED ≥58 Gy had a higher response rate than did those receiving BED &lt; 58 Gy (54.6% vs. 20%, p = 0.034). Toya et al. <ref type="bibr" target="#b9">[9]</ref> have also reported that BED (&lt; 58 vs. ≥58 Gy) was a significant predictor of tumor response and survival. In one pooled analysis of SABR, Ohri et al. <ref type="bibr" target="#b28">[28]</ref> reported that there was no dose response relationship in terms of local control when treating primary liver tumors, which is comparable to our findings. The narrow dose range and small sample size in our study may have led this result. We reasoned that higher objective response resulting from adequate BED contributes to survival benefit. In agreement, a previous hypothesis states that RT may reduce or stabilize PVI, leading to the restoration of vascular flow and slowing down of intrahepatic tumor dissemination, thus halting the deterioration of hepatic function.</p><p>Historically, RT has not been widely used for liver tumors because of a significant risk of RILD, though modern RT techniques have reduced this risk. A RILD incidence of 8-19% for CFRT <ref type="bibr" target="#b29">[29,</ref><ref type="bibr" target="#b30">30]</ref> and 0-5% for SABR <ref type="bibr" target="#b31">[31,</ref><ref type="bibr" target="#b32">32]</ref> has been reported. Moderately higher RILD incidence in our cohort may be explained by less favorable populations included, hepatitis B virus prevalence, and challenge to discern the causes of liver enzyme elevation. In agreement with our findings, CP score increase (another endpoint) was reported in 10 to 30% of primary liver cancer patients after SABR treatment <ref type="bibr" target="#b21">[21,</ref><ref type="bibr" target="#b33">33]</ref>. We chose these endpoints for robust data comparison. In our study, SABR and CFRT had comparable RILD incidences and CP score increases, which was possibly attributable to a relatively small cohort or the similar constraints (with 700 ml normal liver &lt; 15 Gy) applied in both techniques. Even so, SABR leads to an improvement in therapeutic index, as it gives a greater level of clinical benefit for the same level of morbidity.</p><p>The high possibility of failure outside the radiation field implies the necessities for combining regional or systemic treatments with RT. Numerous combinations have been reported, though most were retrospective and poorlyevidenced. A recently-published randomized-controlled trial conducted by Yoon et al. <ref type="bibr" target="#b34">[34]</ref> demonstrated that compared to sorafenib, TACE+3DCRT yielded higher progression-free survival, time to progression, ORR, and OS in HCC with macroscopic vascular invasion. We were unable to detect differences between TACE+SABR versus TACE+CFRT in subgroup analysis in our study. Given the potential superiority of SABR, replacement  of CFRT with SABR is a consideration for future combination investigations. The primary limitation of this study is the retrospective, single-institutional design. Even though propensity score matching minimizes the bias related to treatment assignment, unmeasured confounding may have existed. Further prospective studies are warranted. We note that issues regarding state-of-the-art technology may have affected treatment outcomes. However, we grouped patients into 2 treatment periods in the statistical analysis, which may eliminate this concern.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p>In summary, we demonstrated that compared to CFRT, SABR led to superior ORR, OS, and IFPS in propensity score-matched PVI patients. SABR delivers higher BED without increasing hepatic toxicities, and hence is a suitable RT modality for PVI patients. Further studies are required to validate our results.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc>Example of target delineation in the axial (a) and coronal (b) view of computed tomography scans. The green, red, and blue lines represent detectable portal vein invasion, adjacent tumor, and clinical target volume, respectively</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc>Flow diagram for the selection of hepatocellular carcinoma patients with portal vein invasion</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 4</head><label>4</label><figDesc>Overall survival (a) and in-field progression-free survival (b) in the propensity score-matched cohort using Kaplan Meier method</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 5</head><label>5</label><figDesc>Overall survival considering the biologically effective dose in the entire cohort</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table</head><label></label><figDesc>Patient characteristics of the entire cohort</figDesc><table><row><cell></cell><cell>SABR (n = 54)</cell><cell>CFRT (n = 86)</cell><cell></cell></row><row><cell>Variable</cell><cell>No. of</cell><cell>No. of</cell><cell cols="2">p-value SMD</cell></row><row><cell></cell><cell>patients (%)</cell><cell>patients (%)</cell><cell></cell></row><row><cell>Time of treatment</cell><cell></cell><cell></cell><cell>0.789</cell><cell>0.047</cell></row><row><cell>Before December</cell><cell>27 (50.0)</cell><cell>45 (52.3)</cell><cell></cell></row><row><cell>31, 2011</cell><cell></cell><cell></cell><cell></cell></row><row><cell>After December</cell><cell>27 (50.0)</cell><cell>41 (47.7)</cell><cell></cell></row><row><cell>31, 2011</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age, year</cell><cell></cell><cell></cell><cell>0.494</cell><cell>0.243</cell></row><row><cell>Mean (SD)*,</cell><cell cols="2">61.0 (12.9), 32-84 59.6 (11.2), 34-90</cell><cell></cell></row><row><cell>range</cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤</cell><cell>23 (42.6)</cell><cell>47 (54.7)</cell><cell></cell></row><row><cell>&gt;</cell><cell>31 (57.4)</cell><cell>39 (45.3)</cell><cell></cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell>0.766</cell><cell>0.052</cell></row><row><cell>Male</cell><cell>42 (77.8)</cell><cell>65 (75.6)</cell><cell></cell></row><row><cell>Female</cell><cell>12 (22.2)</cell><cell>21 (24.4)</cell><cell></cell></row><row><cell>Liver disease</cell><cell></cell><cell></cell><cell>0.281</cell><cell>0.086</cell></row><row><cell>HBV</cell><cell>29 (53.7)</cell><cell>56 (65.1)</cell><cell></cell></row><row><cell>HCV</cell><cell>17 (31.5)</cell><cell>16 (18.6)</cell><cell></cell></row><row><cell>HBV and HCV</cell><cell>1 (1.9)</cell><cell>4 (4.7)</cell><cell></cell></row><row><cell>Non-virus</cell><cell>7 (13.0)</cell><cell>10 (11.6)</cell><cell></cell></row><row><cell>ECOG</cell><cell></cell><cell></cell><cell>0.887</cell><cell>0.025</cell></row><row><cell>0-1</cell><cell>46 (85.2)</cell><cell>74 (86.0)</cell><cell></cell></row><row><cell>2</cell><cell>8 (14.8)</cell><cell>12 (14.0)</cell><cell></cell></row><row><cell>Extrahepatic</cell><cell></cell><cell></cell><cell>0.993</cell><cell>0.001</cell></row><row><cell>metastasis</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>5 (9.3)</cell><cell>8 (9.3)</cell><cell></cell></row><row><cell>No</cell><cell>49 (90.7)</cell><cell>78 (90.7)</cell><cell></cell></row><row><cell>AFP, ng/ml</cell><cell></cell><cell></cell><cell>0.960</cell><cell>0.009</cell></row><row><cell>≤200</cell><cell>23 (42.6)</cell><cell>37 (43.0)</cell><cell></cell></row><row><cell>&gt; 200</cell><cell>31 (57.4)</cell><cell>49 (57.0)</cell><cell></cell></row><row><cell>Child-Pugh class</cell><cell></cell><cell></cell><cell>0.086</cell><cell>0.303</cell></row><row><cell>A</cell><cell>35 (64.8)</cell><cell>43 (50.0)</cell><cell></cell></row><row><cell>B</cell><cell>19 (35.2)</cell><cell>43 (50.0)</cell><cell></cell></row><row><cell>Prior treatment</cell><cell></cell><cell></cell><cell>0.047</cell><cell>0.350</cell></row><row><cell>Yes</cell><cell>30 (55.6)</cell><cell>33 (38.4)</cell><cell></cell></row><row><cell>No</cell><cell>24 (44.4)</cell><cell>53 (61.6)</cell><cell></cell></row><row><cell>No. of tumor</cell><cell></cell><cell></cell><cell>0.894</cell><cell>0.023</cell></row><row><cell>Multiple</cell><cell>37 (68.5)</cell><cell>58 (67.4)</cell><cell></cell></row><row><cell>Single</cell><cell>17 (31.5)</cell><cell>28 (32.6)</cell><cell></cell></row><row><cell>Tumor size, cm</cell><cell></cell><cell></cell><cell>0.088</cell><cell>0.298</cell></row><row><cell>≤8</cell><cell>28 (51.9)</cell><cell>32 (37.2)</cell><cell></cell></row><row><cell>&gt; 8</cell><cell>26 (48.1)</cell><cell>54 (62.8)</cell><cell></cell></row><row><cell>PVI location</cell><cell></cell><cell></cell><cell>0.128</cell><cell>0.267</cell></row><row><cell>Vp4</cell><cell>23 (42.6)</cell><cell>48 (55.8)</cell><cell></cell></row><row><cell>Vp3</cell><cell>31 (57.4)</cell><cell>38 (44.2)</cell><cell></cell></row><row><cell>Sorafenib</cell><cell></cell><cell></cell><cell>0.825</cell><cell>0.038</cell></row><row><cell>Yes</cell><cell>23 (42.6)</cell><cell>35 (40.7)</cell><cell></cell></row><row><cell>No</cell><cell>31 (57.4)</cell><cell>51 (59.3)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc>Patient characteristics of the entire cohort (Continued) Abbreviations: SABR Stereotactic ablative radiotherapy, CFRT Conventionally fractionated radiotherapy, HBV Hepatitis B virus, HCV Hepatitis C virus, ECOG Eastern Cooperative Oncology Group, AFP Alpha fetoprotein, PVI Portal vein invasion, BED Biologically effective dose, SD Standard deviation, SMD Standardized mean difference. *t-testpredictors of survival. A receiver operating characteristic (ROC) curve was used to define optimal cut-off points for continuous variables based on the Youden index. Given the imbalance of potential confounders between groups, propensity score-matching was used. Propensity scores were estimated from a logistic regression model that included treatment period, sex, age, prior treatment, virus infection type, performance, tumor size, tumor number, extrahepatic metastasis, PVI location, AFP level, CP class, and sorafenib use. A nearest neighbor method with a caliper width of 0.2 was used to create matched cohorts. A 2-tailed p &lt; 0.05 was designated as statistically significant for all tests except when variables with p &lt; 0.10 in the univariable Cox model</figDesc><table><row><cell></cell><cell>SABR (n = 54)</cell><cell>CFRT (n = 86)</cell><cell></cell></row><row><cell>Variable</cell><cell>No. of</cell><cell>No. of</cell><cell>p-value SMD</cell></row><row><cell></cell><cell>patients (%)</cell><cell>patients (%)</cell><cell></cell></row><row><cell>BED, Gy</cell><cell></cell><cell></cell><cell>&lt; 0.001 1.075</cell></row><row><cell>&lt; 65</cell><cell>14 (25.9)</cell><cell>63 (73.3)</cell><cell></cell></row><row><cell>≥ 65</cell><cell>40 (74.1)</cell><cell>23 (26.7)</cell><cell></cell></row></table><note>were entered into a multivariable Cox model. SPSS (SPSS Inc. Chicago, IL, USA) version 22 and R statistical software version 3.4.3 (R Foundation, https://www.r-project.org)) were used for data analysis.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc>Patient characteristics of the propensity score-matched cohort</figDesc><table><row><cell></cell><cell>SABR (n = 49)</cell><cell>CFRT (n = 49)</cell><cell></cell><cell></cell></row><row><cell>Variable</cell><cell>No. of</cell><cell>No. of</cell><cell cols="2">p-value SMD</cell></row><row><cell></cell><cell>patients (%)</cell><cell>patients (%)</cell><cell></cell><cell></cell></row><row><cell>Time of treatment</cell><cell></cell><cell></cell><cell>0.840</cell><cell>0.041</cell></row><row><cell>Before December</cell><cell>24 (49.0)</cell><cell>23 (46.9)</cell><cell></cell><cell></cell></row><row><cell>31, 2011</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>After December</cell><cell>25 (51.0)</cell><cell>26 (53.1)</cell><cell></cell><cell></cell></row><row><cell>31, 2011</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age, year</cell><cell></cell><cell></cell><cell>0.648</cell><cell>0.082</cell></row><row><cell cols="3">Mean (SD)*, range 60.2 (13.2), 32-84 59.1 (10.9), 34-78</cell><cell></cell><cell></cell></row><row><cell>≤ 60</cell><cell>22 (44.9)</cell><cell>24 (49.0)</cell><cell></cell><cell></cell></row><row><cell>&gt; 60</cell><cell>27 (55.1)</cell><cell>25 (51.0)</cell><cell></cell><cell></cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell>0.812</cell><cell>0.048</cell></row><row><cell>Male</cell><cell>38 (77.6)</cell><cell>37 (75.5)</cell><cell></cell><cell></cell></row><row><cell>Female</cell><cell>11 (22.4)</cell><cell>12 (24.5)</cell><cell></cell><cell></cell></row><row><cell>Liver disease</cell><cell></cell><cell></cell><cell>0.259</cell><cell>0.116</cell></row><row><cell>HBV</cell><cell>28 (57.1)</cell><cell>32 (65.3)</cell><cell></cell><cell></cell></row><row><cell>HCV</cell><cell>14 (28.6)</cell><cell>7 (14.3)</cell><cell></cell><cell></cell></row><row><cell>HBV and HCV</cell><cell>1 (2.0)</cell><cell>3 (6.1)</cell><cell></cell><cell></cell></row><row><cell>Non-virus</cell><cell>6 (12.2)</cell><cell>7 (14.3)</cell><cell></cell><cell></cell></row><row><cell>ECOG</cell><cell></cell><cell></cell><cell>0.790</cell><cell>0.054</cell></row><row><cell>0-1</cell><cell>41 (83.7)</cell><cell>40 (81.6)</cell><cell></cell><cell></cell></row><row><cell>2</cell><cell>8 (16.3)</cell><cell>9 (18.4)</cell><cell></cell><cell></cell></row><row><cell>Extrahepatic</cell><cell></cell><cell></cell><cell>1.000</cell><cell>&lt; 0.001</cell></row><row><cell>metastasis</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>5 (10.2)</cell><cell>5 (10.2)</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>44 (89.8)</cell><cell>44 (89.8)</cell><cell></cell><cell></cell></row><row><cell>AFP, ng/ml</cell><cell></cell><cell></cell><cell>0.541</cell><cell>0.124</cell></row><row><cell>≤200</cell><cell>20 (40.8)</cell><cell>23 (46.9)</cell><cell></cell><cell></cell></row><row><cell>&gt; 200</cell><cell>29 (59.2)</cell><cell>26 (53.1)</cell><cell></cell><cell></cell></row><row><cell>Child-Pugh class</cell><cell></cell><cell></cell><cell>0.835</cell><cell>0.042</cell></row><row><cell>A</cell><cell>31 (63.3)</cell><cell>30 (61.2)</cell><cell></cell><cell></cell></row><row><cell>B</cell><cell>18 (36.7)</cell><cell>19 (38.8)</cell><cell></cell><cell></cell></row><row><cell>Prior treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>25 (51.0)</cell><cell>28 (57.1)</cell><cell>0.543</cell><cell>0.123</cell></row><row><cell>No</cell><cell>24 (49.0)</cell><cell>21 (42.9)</cell><cell></cell><cell></cell></row><row><cell>No. of tumor</cell><cell></cell><cell></cell><cell>0.828</cell><cell>0.044</cell></row><row><cell>Multiple</cell><cell>34 (69.4)</cell><cell>33 (67.3)</cell><cell></cell><cell></cell></row><row><cell>Single</cell><cell>15 (30.6)</cell><cell>16 (32.7)</cell><cell></cell><cell></cell></row><row><cell>Tumor size, cm</cell><cell></cell><cell></cell><cell>1.000</cell><cell>&lt; 0.001</cell></row><row><cell>≤8</cell><cell>24 (49.0)</cell><cell>24 (49.0)</cell><cell></cell><cell></cell></row><row><cell>&gt; 8</cell><cell>25 (51.0)</cell><cell>25 (51.0)</cell><cell></cell><cell></cell></row><row><cell>PVI location</cell><cell></cell><cell></cell><cell>1.000</cell><cell>&lt; 0.001</cell></row><row><cell>Vp4</cell><cell>21 (42.9)</cell><cell>21 (42.9)</cell><cell></cell><cell></cell></row><row><cell>Vp3</cell><cell>28 (57.1)</cell><cell>28 (57.1)</cell><cell></cell><cell></cell></row><row><cell>Sorafenib</cell><cell></cell><cell></cell><cell>1.000</cell><cell>&lt; 0.001</cell></row><row><cell>Yes</cell><cell>21 (42.9)</cell><cell>21 (42.9)</cell><cell></cell><cell></cell></row><row><cell>No</cell><cell>28 (57.1)</cell><cell>28 (57.1)</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc>Patient characteristics of the propensity score-matched cohort (Continued)</figDesc><table><row><cell></cell><cell>SABR (n = 49)</cell><cell>CFRT (n = 49)</cell><cell></cell></row><row><cell>Variable</cell><cell>No. of</cell><cell>No. of</cell><cell>p-value SMD</cell></row><row><cell></cell><cell>patients (%)</cell><cell>patients (%)</cell><cell></cell></row><row><cell>BED, Gy</cell><cell></cell><cell></cell><cell>&lt; 0.001 1.124</cell></row><row><cell>&lt; 65</cell><cell>13 (26.5)</cell><cell>37 (75.5)</cell><cell></cell></row><row><cell>≥ 65</cell><cell>36 (73.5)</cell><cell>12 (24.5)</cell><cell></cell></row><row><cell cols="4">Abbreviations: SABR Stereotactic ablative radiotherapy, CFRT Conventionally</cell></row><row><cell cols="4">fractionated radiotherapy, HBV Hepatitis B virus, HCV Hepatitis C virus,</cell></row><row><cell cols="4">ECOG Eastern Cooperative Oncology Group, AFP Alpha fetoprotein, PVI</cell></row><row><cell cols="4">Portal vein invasion, BED Biologically effective dose, SD Standard deviation,</cell></row><row><cell cols="3">SMD Standardized mean difference. *t-test</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3</head><label>3</label><figDesc>Univariable and multivariable analysis of the entire cohort</figDesc><table><row><cell></cell><cell>Univariable</cell><cell></cell><cell cols="2">Multivariable (model 1)  †</cell><cell cols="2">Multivariable (model 2)  †</cell></row><row><cell>Variable</cell><cell>HR (95% CI)</cell><cell>p</cell><cell>HR (95% CI)</cell><cell>p</cell><cell>HR (95% CI)</cell><cell>p</cell></row><row><cell>SABR vs. CFRT</cell><cell>0.615 (0.410-0.924)</cell><cell>0.019</cell><cell>0.623 (0.427-0.909)</cell><cell>0.014</cell><cell></cell><cell></cell></row><row><cell>BED &lt; 65 vs. ≥ 65</cell><cell>1.482 (1.039-2.115)</cell><cell>0.030</cell><cell></cell><cell></cell><cell>1.682 (1.150-2.462)</cell><cell>0.007</cell></row><row><cell>Time of treatment Before December 31,</cell><cell>1.008 (0.706-1.439)</cell><cell>0.965</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>2011 vs. after December 31, 2011</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age ≤ 60 vs. &gt; 60</cell><cell>0.882 (0.586-1.327)</cell><cell>0.547</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Sex male vs. female</cell><cell>1.094 (0.687-1.741)</cell><cell>0.706</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>ECOG 0-1 vs. 2</cell><cell>0.554 (0.315-0.977)</cell><cell>0.041</cell><cell>0.523 (0.312-0.877)</cell><cell>0.014</cell><cell>0.572 (0.342-0.957)</cell><cell>0.033</cell></row><row><cell>Extrahepatic metastasis yes vs. no</cell><cell>1.731 (0.860-3.484)</cell><cell>0.124</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>AFP ≤200 vs. &gt; 200</cell><cell>0.606 (0.424-0.866)</cell><cell>0.006</cell><cell>0.566 (0.378-0.846)</cell><cell>0.006</cell><cell>0.520 (0.344-0.785)</cell><cell>0.002</cell></row><row><cell>Child-Pugh class A vs. B</cell><cell>0.383 (0.249-0.588)</cell><cell>&lt; 0.001</cell><cell>0.560 (0.381-0.823)</cell><cell>0.003</cell><cell>0.511 (0.345-0.756)</cell><cell>0.001</cell></row><row><cell>Prior Treatment yes vs no</cell><cell>0.690 (0.483-0.986)</cell><cell>0.042</cell><cell>0.955 (0.647-1.410)</cell><cell>0.816</cell><cell>0.903 (0.607-1.343)</cell><cell>0.615</cell></row><row><cell>Single vs. multiple</cell><cell>0.379 (0.233-0.617)</cell><cell>&lt; 0.001</cell><cell>0.494 (0.323-0.756)</cell><cell>0.001</cell><cell>0.474 (0.308-0.729)</cell><cell>0.001</cell></row><row><cell>Tumor size ≤8 vs. &gt; 8</cell><cell>0.452 (0.296-0.689)</cell><cell>&lt; 0.001</cell><cell>0.538 (0.360-0.804)</cell><cell>0.002</cell><cell>0.550 (0.367-0.825)</cell><cell>0.004</cell></row><row><cell>Vp3 vs. Vp4</cell><cell>0.641 (0.426-0.964)</cell><cell>0.033</cell><cell>0.678 (0.467-0.985)</cell><cell>0.041</cell><cell>0.685 (0.471-0.995)</cell><cell>0.047</cell></row><row><cell>Sorafenib yes vs. no</cell><cell>0.980 (0.685-1.401)</cell><cell>0.911</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note>Abbreviations: SABR Stereotactic ablative radiotherapy, BED Biologically effective dose, ECOG Eastern Cooperative Oncology Group, EM Extrahepatic metastasis, AFP Alpha feto protein, HR Hazard ratio, CI Confidence interval †BED correlated highly with radiotherapy technique. Two Cox models were used to avoid collinearity</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4</head><label>4</label><figDesc>Acute toxicity observed due to SABR and CFRT in the entire cohort</figDesc><table><row><cell></cell><cell>SABR</cell><cell></cell><cell></cell><cell>CFRT</cell><cell></cell><cell></cell></row><row><cell></cell><cell>No. of patients (%)</cell><cell></cell><cell></cell><cell>No. of patients (%)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Grade 1</cell><cell>Grade 2</cell><cell>Grade 3</cell><cell>Grade 1</cell><cell>Grade 2</cell><cell>Grade 3</cell><cell>Grade 5</cell></row><row><cell>Nausea</cell><cell>5(9.3)</cell><cell>2(3.7)</cell><cell></cell><cell>9(10.5)</cell><cell>3(3.5)</cell><cell></cell></row><row><cell>Vomiting</cell><cell>3(5.6)</cell><cell>1(1.8)</cell><cell></cell><cell>2(2.3)</cell><cell>1(1.2)</cell><cell></cell></row><row><cell>Abdominal pain</cell><cell>9 (16.7)</cell><cell>2(3.7)</cell><cell>1(1.9)</cell><cell>6(7.0)</cell><cell></cell><cell></cell></row><row><cell>Diarrhea</cell><cell>1(1.9)</cell><cell>1(1.9)</cell><cell></cell><cell>6(7.0)</cell><cell>4(4.7)</cell><cell>2(2.3)</cell></row><row><cell>Fatigue</cell><cell>11 (20.3)</cell><cell>2(3.7)</cell><cell></cell><cell>17 (19.8)</cell><cell>1(1.2)</cell><cell></cell></row><row><cell>Anorexia</cell><cell>10 (18.5)</cell><cell>2(3.7)</cell><cell></cell><cell>10 (11.6)</cell><cell>1(1.2)</cell><cell></cell></row><row><cell>Duodenal ulcer</cell><cell></cell><cell>2(3.7)</cell><cell></cell><cell></cell><cell>1(1.2)</cell><cell></cell><cell>1(1.2)</cell></row></table><note>Abbreviations: SABR Stereotactic ablative radiotherapy, CFRT Conventionally fractionated radiotherapy</note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>We thank the Cancer Registry of the Tri-Service General Hospital for helping in data collection.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Authors' contributions WYH provided the conception of this study. WYH, CSL and HLC designed the study. JFY, MSL, YHD and PCS analyzed and interpreted the patient data. JFY drafted the manuscript and WYH edited the manuscript. All authors read and approved the final manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p>This study was supported in part by the study projects of TSGH-C107-035&amp; TSGH-PH-108-5 &amp; CMNDMC10805.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p>The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p>Waiver of consent for this retrospective research was obtained from the institutional review board of Tri-Service General Hospital (approval number: 1-107-05-016).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p>The authors declare that they have no competing interests. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author details</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's Note</head><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pirisi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Avellini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Fabris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Bardus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Soardo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="397" to="400" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Hepatocellular carcinoma in the United States. Prognostic feature, treatment outcome, and survival</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">E</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Anand</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Jenkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="2217" to="2239" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Llovet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bustamante</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Castells</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Vilana</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ayuso</forename><surname>Mdel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Sala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="62" to="69" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancer Version 1</title>
		<ptr target="//www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf&gt;" />
		<imprint>
			<date type="published" when="2018" />
		</imprint>
		<respStmt>
			<orgName>National Comprehensive Cancer Network (NCCN</orgName>
		</respStmt>
	</monogr>
	<note>National Comprehensive Cancer Network</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">European Association for Study of Liver</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma</title>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="599" to="641" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Sorafenib in advanced hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Llovet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ricci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Mazzaferro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Hilgard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Gane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">F</forename><surname>Blanc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="378" to="90" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">K</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Tsao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="25" to="34" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">C</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">X</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="432" to="475" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Toya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Morishita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Ikeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="266" to="71" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1155" to="63" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Nakazawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Komori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Hidaka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Okuwaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Takada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="352" to="359" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Efficacy of external beam radiation-based treatment plus locoregional therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">F</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>Chou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">6017406</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Senan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Mehran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">V</forename><surname>Louie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Balter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="630" to="637" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Chuong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">M</forename><surname>Springett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Freilich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Mellon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="516" to="538" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bruix</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sherman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1020" to="1022" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy in recurrent hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Jen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">P</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="355" to="61" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Modified RECIST (mRECIST) assessment for hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Lencioni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Llovet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Liver Dis</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="52" to="60" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">O</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">B</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">N</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Bae</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">351</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Que</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">W</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">120</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Xi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><forename type="middle">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">Z</forename><surname>Feng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">63864</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Bujold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Massey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Brierley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1631" to="1640" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis/inferior vena cava tumor thrombosis: evaluation by comparison with conventional three-dimensional conformal radiotherapy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Matsuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Nishimura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Ejima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Miyawaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Uezono</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Radiat Res</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="512" to="535" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis and systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Rim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">S</forename><surname>Yoon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="112" to="134" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">B</forename><surname>Holliday</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Brownlee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="39" to="45" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">I</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Bae</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiat Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">250</biblScope>
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">S</forename><surname>Chadha</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Gunther</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Hsieh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="54" to="61" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">C</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Paik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="2419" to="2445" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Local control after stereotactic body radiation therapy for liver tumors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Ohri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">A</forename><surname>Tomé</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Méndez</forename><surname>Romero</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Miften</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ten Haken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page">34525</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Analysis of radiation-induced liver disease using the Lyman NTCP model</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Normolle</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Balter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Mcginn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ten</forename><surname>Haken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="810" to="831" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiationinduced liver disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Jian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1502" to="1511" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">V</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hawkins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lockwood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Knox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="657" to="64" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Phase I study of individualized stereotactic body radiotherapy of liver metastases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Dinniwell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Brierley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lockwood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1585" to="91" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Son</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">O</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">R</forename><surname>Ryu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">N</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Bae</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1073" to="80" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Efficacy and safety of Transarterial chemoembolization plus external beam radiotherapy vs Sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">Y</forename><surname>Ryoo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Shin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>An</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="661" to="670" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
